Literature DB >> 24933343

Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression.

M Siebelt1, J H Waarsing2, H C Groen3, C Müller4, S J Koelewijn3, E de Blois3, J A N Verhaar2, M de Jong5, H Weinans6.   

Abstract

Osteoarthritis (OA) is a non-rheumatoid joint disease characterized by progressive degeneration of extra-cellular cartilage matrix (ECM), enhanced subchondral bone remodeling, osteophyte formation and synovial thickening. Alendronate (ALN) is a potent inhibitor of osteoclastic bone resorption and results in reduced bone remodeling. This study investigated the effects of pre-emptive use of ALN on OA related osteoclastic subchondral bone resorption in an in vivo rat model for severe OA. Using multi-modality imaging we measured effects of ALN treatment within cartilage and synovium. Severe osteoarthritis was induced in left rat knees using papain injections in combination with a moderate running protocol. Twenty rats were treated with subcutaneous ALN injections and compared to twenty untreated controls. Animals were longitudinally monitored for 12weeks with in vivo μCT to measure subchondral bone changes and SPECT/CT to determine synovial macrophage activation using a folate-based radiotracer. Articular cartilage was analyzed at 6 and 12weeks with ex vivo contrast enhanced μCT and histology to measure sulfated-glycosaminoglycan (sGAG) content and cartilage thickness. ALN treatment successfully inhibited subchondral bone remodeling. As a result we found less subchondral plate porosity and reduced osteophytosis. ALN treatment did not reduce subchondral sclerosis. However, after the OA induction phase, ALN treatment protected cartilage ECM from degradation and reduced synovial macrophage activation. Surprisingly, ALN treatment also improved sGAG content of tibia cartilage in healthy joints. Our data was consistent with the hypothesis that osteoclastic bone resorption might play an important role in OA and may be a driving force for progression of the disease. However, our study suggest that this effect might not solely be effects on osteoclastic activity, since ALN treatment also influenced macrophage functioning. Additionally, ALN treatment and physical activity exercised a positive effect in healthy control joints, which increased cartilage sGAG content. More research on this topic might lead to novel insights as to improve cartilage quality.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alendronate; Articular cartilage; Exercise; Osteoarthritis; Osteoclast; Subchondral bone

Mesh:

Substances:

Year:  2014        PMID: 24933343     DOI: 10.1016/j.bone.2014.06.009

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  23 in total

1.  Osteoarthritis: alendronate treatment improves pathology in animal model of OA by blocking osteoclastic bone resorption.

Authors:  João H Duarte
Journal:  Nat Rev Rheumatol       Date:  2014-07-08       Impact factor: 20.543

2.  Role of subchondral bone properties and changes in development of load-induced osteoarthritis in mice.

Authors:  O O Adebayo; F C Ko; P T Wan; S R Goldring; M B Goldring; T M Wright; M C H van der Meulen
Journal:  Osteoarthritis Cartilage       Date:  2017-09-14       Impact factor: 6.576

3.  99Tc-Methylene Diphosphonate Treatment is Safe and Efficacious for Osteoporosis in Postmenopausal Differentiated Thyroid Cancer Patients Undergoing TSH Suppression: A Three-Center Non-Randomized Clinical Study.

Authors:  Jianhao Xie; XueYu Yuan; Weiqing Mao; Haidong Cai; Kejia Gao; Zhongwei Lv; Hui Wang; Chao Ma
Journal:  Cancer Manag Res       Date:  2022-03-05       Impact factor: 3.989

4.  Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via suppressing ERK/c-fos/NFATc1 pathway, and subsequently inhibiting subchondral osteoclast fusion.

Authors:  Chao Fang; Jia-Wei Guo; Ya-Jun Wang; Xiao-Qun Li; Hao Zhang; Jin Cui; Yan Hu; Ying-Ying Jing; Xiao Chen; Jia-Can Su
Journal:  Acta Pharmacol Sin       Date:  2021-08-11       Impact factor: 7.169

5.  Knee loading inhibits osteoclast lineage in a mouse model of osteoarthritis.

Authors:  Xinle Li; Jing Yang; Daquan Liu; Jie Li; Kaijun Niu; Shiqing Feng; Hiroki Yokota; Ping Zhang
Journal:  Sci Rep       Date:  2016-04-18       Impact factor: 4.379

6.  Bone repair in craniofacial defects treated with different doses of alendronate: a histological, histomorphometric, and immunohistochemical study.

Authors:  Naylin de Oliveira; Jefferson Oliveira; Letícia de Souza Moraes; Suyany Gabriely Weiss; Luís Henrique Chaves; Thais Costa Casagrande; Tatiana Miranda Deliberador; Allan Fernando Giovanini; João César Zielak; Rafaela Scariot
Journal:  Clin Oral Investig       Date:  2018-10-09       Impact factor: 3.573

7.  Acupotomy Contributes to Suppressing Subchondral Bone Resorption in KOA Rabbits by Regulating the OPG/RANKL Signaling Pathway.

Authors:  Tong Wang; Yan Guo; Xiao-Wei Shi; Yang Gao; Jia-Yi Zhang; Chun-Jiu Wang; Xue Yang; Qi Shu; Xi-Lin Chen; Xin-Yi Fu; Wen-Shan Xie; Yi Zhang; Bin Li; Chang-Qing Guo
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-26       Impact factor: 2.629

8.  Early Alterations of Subchondral Bone in the Rat Anterior Cruciate Ligament Transection Model of Osteoarthritis.

Authors:  Nik Aizah; Pan Pan Chong; Tunku Kamarul
Journal:  Cartilage       Date:  2019-09-30       Impact factor: 3.117

9.  Early inhibition of subchondral bone remodeling slows load-induced posttraumatic osteoarthritis development in mice.

Authors:  Sophia N Ziemian; Ana M Witkowski; Timothy M Wright; Miguel Otero; Marjolein C H van der Meulen
Journal:  J Bone Miner Res       Date:  2021-07-16       Impact factor: 6.390

10.  Low bone mass resulting from impaired estrogen signaling in bone increases severity of load-induced osteoarthritis in female mice.

Authors:  Sophia N Ziemian; Olufunmilayo O Ayobami; Amanda M Rooney; Natalie H Kelly; Derek T Holyoak; F Patrick Ross; Marjolein C H van der Meulen
Journal:  Bone       Date:  2021-06-24       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.